Interim results from ASPIRE, a randomized, open-label, multicenter phase 3 study evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma

被引：0

作者：

Stewart, A. K. ^{[1
]}

Rajkumar, S. V. ^{[2
]}

Dimopoulos, M. A. ^{[3
]}

Mihaylov, G. G. ^{[4
]}

Goranova-Marinova, V. ^{[5
]}

Rajnics, P. ^{[6
]}

Suvorov, A. ^{[7
]}

Jakubowiak, A. J. ^{[8
]}

San-Miguel, J. F. ^{[9
]}

Zojwalla, N. ^{[10
]}

Moreau, P. ^{[11
]}

Palumbo, A. ^{[12
]}

机构：

[1] Mayo Clin, Scottsdale, AZ USA

[2] Mayo Clin, Div Hematol, Rochester, MN USA

[3] Alexandra Hosp, Athens, Greece

[4] Queen Joanna Univ Hosp, Sofia, Bulgaria

[5] Hematol Clin Univ Multiprofile Hosp Act Treatment, Plovdiv, Bulgaria

[6] Mor Kaposi Teaching Hosp, Dept Hematol, Kaposvar, Hungary

[7] First Republican Clin Hosp Udmurtia, Dept Hematol, Izhe Versusk, Russia

[8] Univ Chicago Med Ctr, Chicago, IL USA

[9] Univ Navarra Clin, Pamplona, Spain

[10] Onyx Pharmaceut Inc, San Francisco, CA USA

[11] Univ Nantes, Nantes, France

[12] Univ Turin, I-10124 Turin, Italy

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：20 / 20

页数：1